

**REMARKS**

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow. Applicants believe the title is descriptive and respectfully request reconsideration of this objection.

**Drawings**

The present application was filed with drawings. Acceptance of these drawings by checking the appropriate box in the Notice of Allowability or the Office Action Summary is respectfully requested in the next communication from the examiner.

**Priority**

The present application is a national phase application of an international application. Because the present application is a national phase application and not a continuation application, amendment of the specification is not required. The below passage from MPEP 1893.03(d) is instructive on this point. Moreover, applicants have filed an ADS, which under the new Rule 37 CFR 1.78, obviates the requirement for amending the specification to recite the priority information.

MPEP 1893.03(d)

Note: a national stage application submitted under 35 U.S.C. 371 may not claim benefit of the filing date of the international application of which it is the national stage since its filing date is the date of filing of that international application. See also MPEP § 1893.03(b). Stated differently, since the international application is not an earlier application (it has the same filing date as the national stage), a benefit claim under 35 U.S.C. 120 in the national stage to the international application is inappropriate and may result in the submission being treated as an application filed under 35 U.S.C. 111(a). See MPEP § 1893.03(a). Accordingly, it is not necessary for the applicant to amend the first sentence(s) of the specification to reference the international application number that was used to identify the application during international processing of the application by the international authorities prior to commencement of the national stage.

**Prior Art Rejection**

The cited Genentech patent, US 6,737,056, only relates to the modification of the Fc region of antibodies by amino-acid substitution to increase ADCC activity. Nowhere can be found any reference to a modification of antibodies glycosylation in this document. Therefore the present claims are novel over the prior art. The present amendment also overcomes the rejections under Section 101.


**Conclusion**

Applicants believe the present claims are allowable.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date: April 5, 2006

By 

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5300  
Facsimile: (202) 672-5399

Matthew E. Mulkeen  
Attorney for Applicants  
Registration No. 44,250